Oncolytic viruses for multiple myeloma therapy

Christine M. Calton, Kevin R. Kelly, Faiz Anwer, Jennifer S. Carew, Steffan T. Nawrocki

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therapeutics that provide tumor-targeted therapy by specifically infecting and replicating within cancerous cells. Oncolytic therapy yields results from both direct killing of malignant cells and induction of an anti-tumor immune response. In this review, we will describe oncolytic viruses that are being tested for MM therapy with a focus on those agents that have advanced into clinical trials.

Original languageEnglish (US)
Article number198
JournalCancers
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 14 2018
Externally publishedYes

    Fingerprint

Keywords

  • Adenovirus
  • Measles virus
  • Multiple myeloma
  • Myxoma virus
  • Oncolytic virotherapy
  • Reovirus
  • Vaccinia virus
  • Vesicular stomatitis virus

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Calton, C. M., Kelly, K. R., Anwer, F., Carew, J. S., & Nawrocki, S. T. (2018). Oncolytic viruses for multiple myeloma therapy. Cancers, 10(6), [198]. https://doi.org/10.3390/cancers10060198